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Can the syndrome of transient epileptic amnesia
be the ﬁrst feature of Alzheimer’s disease?
1. Case report
Transient epileptic amnesia (TEA) is a speciﬁc type of temporal
lobe seizure involving the hippocampus and the parahippocampal
gyrus,1 which can be recognized with now published criteria.2 The
etiology of TEA is still under debate and probably not unique. Apart
from rare patients showing structural lesions on brain MRI,2
microvascular brain load and/or immune-mediated neuronal
aggression have been proposed as alternative causes. A neurode-
generative process is also possible, as suggested by decreased
hippocampal volume and ongoing memory complaints despite
seizure freedom in many treated subjects.1 Thus, late onset
Alzheimer’s disease (LOAD) logically appears as a potential cause
of TEA. Indeed, we present a case of TEA that secondarily evolved
into AD 16 years after seizures onset.
The patient was right-handed and had 9 years of education. She
had no remarkable medical history. Her mother had been
diagnosed with LOAD at the age of 70. The patient was 64 when
she came in 2009 to our Memory Clinic for cognitive complaints
developing since her ﬁrst transient antero-retrograde amnesia (in
1994) that lasted about 10 h and started with a preceding aura
(ascending thoraco-abdominal pain with diffuse heat sensation
and nausea) while witnesses described contact loss for 2 min,
bilateral arm dystonia and oral automatisms (tongue smacking).
Transient global amnesia (TGA) was diagnosed because screening
blood tests, brain CT scan and EEG were all within the normal
range. In 1994, her MMSE score was 30/30, even though she was
complaining of abnormal long term forgetting and autobiographi-
cal difﬁculties (she did not remember her wedding or several
vacations during the previous 10 years). Another antero-retro-
grade amnesia occurred 5 years later (1999), which lasted 2 h and
was preceded by the same aura and a sudden fall. Witnesses again
described partial contact loss during amnesia. CT-scan and EEG
were still normal as was the cardiovascular work-up. Thereafter,
the patient became depressed and the subjective cognitive
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Fig. 1. Evolution of brain atrophy in 5 years. (A) Normal brain MRI (coronal T1-
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizweighted sequence) in October 2009; (B) same sequence showing bilateral
hippocampal and subcortical atrophy 3 years later (October 2012); (C) further
progression of the same pattern of atrophy 5 years later (April 2014).impairment worsened but her MMSE score remained at 30/30:
there was no further memory examination. In 2000, another
amnestic episode happened and lasted 12 h. Six years after, thehttp://dx.doi.org/10.1016/j.seizure.2014.07.008
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hyposmia: she underwent speciﬁc tests in 2006, which returned
normal results (MMSE score = 28/30; preserved memory, visuo-
construction, language and executive functions). In 2009, memory
problems had even more worsened: her MMSE score was 24/30
accompanied by memory impairment (storage deﬁcit) on the Free
and Cued Selective Recall Reminding Test whereas other functions
were normal. The patient also described monthly stereotyped
‘‘syncope-like’’ attacks occurring since the early 2000s and
consisting in ascending aura, tachycardia, fading of perceptions,
dizziness and incipient unconsciousness lasting 1–5 min (average
2 min), sometimes followed by temporo-spatial disorientation and
anterograde amnesia for 20–60 min. We therefore suspected
temporal lobe epilepsy (TLE): brain MRI (Fig. 1) and video-EEG
were normal but treatment with lamotrigine (200 mg daily)
provided a clear-cut response on the amnestic and ‘‘syncope-like’’
events, since there was no recurrence during the following 5 years.
Nevertheless, the patient did not feel any improvement in her
cognitive difﬁculties. In 2010, a lumbar puncture yielded results
supporting AD neuropathology, with Ab42 = 193 pg/ml (N = 500–
1500); P-Tau = 72 pg/ml (N = 0–60); T-Tau = 473 pg/ml (N = 100–
450); IATI (Innotest Abeta tau index) = 0.24 (N > 1.2). Moreover,
other CSF analyses were negative (blood cell count, IgG index,
antineuron antibodies, oligo-clonal bands, Lyme and syphilis
serologies). Rivastigmine (9.5 mg daily) provided a clear subjective
alleviation of memory problems with slight objective improve-
ment on MMSE (25/30). MRI and MMSE changes in the following 5
years are shown in Figs. 1 and 2, respectively.
The diagnosis of AD is consistent with the initial memory
proﬁle of the patient (storage deﬁcits) and her positive CSF
biomarkers. Furthermore, she has now converted to dementia
with hippocampal atrophy (Fig. 1), and she presented decreased
MMSE scores on the past 5 years (Fig. 2). On the other hand, theFig. 2. Evolution of MMSE score from 1994 to 2014. A, B, C, transient epilepdiagnosis of TLE is also probable despite the normality of
repetitive EEGs in view of several arguments. First, the amnestic
episodes were TEA and not TGA according to their frequency
(>20 when taking into account the ‘‘syncope-like’’  events
followed by transient amnesia), their semiology (preceding aura,
loss of contact, arm dystonia, oral automatisms) and their
response to lamotrigine. In fact, the diagnostic criteria for TEA are
fulﬁlled here.2 Second, other ictal events (ascending aura, nausea,
chest pain, duration < 3 min) were compatible with TLE and
were likewise responsive to lamotrigine.
Considering the diagnosis of AD and TLE, the negativity of the
medical workup (including standard blood tests, antineuron
antibodies, brain MRI and CSF analysis) and the chronological
sequence of events (Fig. 2), it is possible that TLE was the ﬁrst
symptom of AD in this case. But we cannot be entirely sure since
AD is a common disease in older patients whilst TEA is a quite rare
syndrome: their association in the present case could only be
coincidental rather than truly causal. Yet, our report is in
accordance with mice models showing that amyloid cascade leads
to early epileptogenic excitatory remodeling in the hippocampus
and to subsequent inhibitory compensatory responses contribut-
ing to memory impairment.3 From this point of view, the treatment
with lamotrigine and rivastigmine may have contributed to the
long-term stabilization of the MMSE of our patient (Fig. 2).
Moreover, a recently published work on the natural history of
sporadic AD has shown an increasing Ab burden in the brain from
15 to 25 years before cognitive symptoms. Taken together, all these
data suggest that amyloid deposition is likely to have begun in our
patient at the time of her ﬁrst seizure (TEA).4
In conclusion, it is plausibe that incipient AD accounts for some
TEAs shortly followed by memory complaints whereas brain
imaging and routine cognitive testing are inconclusive at this
stage. Further studies are needed to determine which patients aretic amnesia misdiagnosed as TGA in 1994, 1999 and 2000 respectively.
Letter to the Editor / Seizure 23 (2014) 918–920920concerned. But TEA should no longer be regarded as a benign
clinical condition: patients should not be reassured too hastily.
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